Key takeaways for Nebraska
- • FDA labels require BMI 30+ or 27+ with comorbidity for approved weight-loss GLP-1s.
- • Mean weight loss: roughly 15% with semaglutide, roughly 21% with tirzepatide at one year.
- • Weight regain is common after stopping — most clinicians frame this as chronic therapy.
- • Nebraska Medicaid (Heritage Health) coverage rules apply for Obesity / Chronic Weight Management patients in Nebraska — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Obesity / Chronic Weight Management
Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) are FDA-approved specifically for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. Evidence grade: A. STEP and SURMOUNT trial programs established mean total body weight loss of approximately 15% with semaglutide 2.4 mg and approximately 21% with tirzepatide 15 mg at 72 weeks. Saxenda (liraglutide 3.0 mg) is also approved but less effective. Weight regain is common after discontinuation, so most experts treat obesity as chronic and indefinite, similar to hypertension.
Nebraska-specific context
Nebraska has telehealth access concentrated in Omaha, Lincoln, Bellevue metros, with additional reach to Grand Island and Kearney. Nebraska Medicine, CHI Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at dhhs.ne.gov.
Nebraskatelehealth & pricing rules
- • Nebraska permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • Nebraska allows new-patient telehealth prescribing without a prior in-person visit.